<DOC>
	<DOCNO>NCT01475994</DOCNO>
	<brief_summary>This mono-center , randomize , double-blind , placebo-controlled , parallel-group study assess effect challenge dactylis glomerata pollen environmental challenge chamber dermal symptom patient suffer atopic dermatitis . After challenge session Day 3 , Day 4 , Day 5 blood sample take biomarker assessment . The severity atopic dermatitis rat `` SCORing Atopic Dermatitis '' ( SCORAD ) , objective SCORAD assessment itch sleeplessness refer past 24 hour blind observer ( trained dermatologist ) day include baseline assessment .</brief_summary>
	<brief_title>Effect Pollen Challenges Dermal Symptoms Patients With Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Male female subject , age 1865 year . Women consider inclusion : Not pregnant , confirmed pregnancy test ( see flow chart ) nursing . Of nonchild bear potential ( i.e . physiologically incapable become pregnant , include female premenarchial postmenopausal , document proof hysterectomy tubal ligation , meet clinical criterion menopause amenorrhoeic 1 year prior screen visit ) . Of childbearing potential use highly effective method contraception entire study ( vasectomised partner , sexual abstinence lifestyle female complete abstinence intercourse two week prior first dose study medication least 72 hour last pollen challenge , implant , injectables , combine oral contraceptive , hormonal IUDs doublebarrier method , i.e . double combination IUD , condom spermicidal gel , diaphragm , sponge , cervical cap ) . Positive IgE level Dactylis glomerata least CAP FEIA class 3. atopic dermatitis ( AD ) fulfil UK criterion AD SCORAD 20 50 point . forced Expiratory Volume first second ( FEV1 ) ≥ 80 % pred . screen . Smokers nonsmoker . Body Mass Index ≥18 ≤ 35 . • Past present disease , judge investigator , may affect outcome study . These disease include , limited , cardiovascular disease , malignancy , hepatic disease , renal disease , hematological disease , neurological disease , endocrine disease pulmonary disease . Asthma mild asthma treat short act beta2agonists control accord current GINA guideline Clinically relevant abnormality haematology , blood chemistry , urinalysis screening . Positive HIV1/2Ab , hepatitis B surface antigen ( HBsAg ) hepatitis C virus antibody ( HCVAb ) test screening . Treatment medication might interfere rescue medication anaphylactic reaction ( e.g . beta blocker ) . Topical steroid treatment ( wash phase : 2 week ) Topical calcineurin inhibitor treatment ( wash phase 2 week ) UV radiation treatment ( wash phase 4 week ) Systemic immunosuppression treatment ( steroid , cyclosporine , azathioprine , Mycophenolat Mofetil ( MMF ) ; wash phase 4 week ) Treatment antihistamine ( wash phase 1 week ) Unstable AD Screening ( SCORAD difference &gt; 10 point Visit 1 Visit 2 ) Diastolic blood pressure 95 mmHg . Febrile illness within 2 week prior screen . Alcohol drug abuse within 12 month prior screen . Regular daily consumption 1 liter usual beer equivalent quantity approximately 40 g alcohol another form . Participation another clinical trial 30 day prior enrolment . There risk noncompliance study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>